CN102597770B - α-甲基葡萄糖苷(AMG)作为葡萄糖吸收和排泄的指示剂的用途 - Google Patents

α-甲基葡萄糖苷(AMG)作为葡萄糖吸收和排泄的指示剂的用途 Download PDF

Info

Publication number
CN102597770B
CN102597770B CN201080051671.0A CN201080051671A CN102597770B CN 102597770 B CN102597770 B CN 102597770B CN 201080051671 A CN201080051671 A CN 201080051671A CN 102597770 B CN102597770 B CN 102597770B
Authority
CN
China
Prior art keywords
amg
animal
sample
amount
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080051671.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102597770A (zh
Inventor
K.T.德马雷斯特
J.M.伦哈德
G.C.利奥
Y.梁
T.L.马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN102597770A publication Critical patent/CN102597770A/zh
Application granted granted Critical
Publication of CN102597770B publication Critical patent/CN102597770B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080051671.0A 2009-09-15 2010-09-14 α-甲基葡萄糖苷(AMG)作为葡萄糖吸收和排泄的指示剂的用途 Expired - Fee Related CN102597770B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24257009P 2009-09-15 2009-09-15
US61/242570 2009-09-15
PCT/US2010/048752 WO2011034846A1 (en) 2009-09-15 2010-09-14 Use of alpha-methylglucoside (amg) as an indicator for glucose absorption and excretion

Publications (2)

Publication Number Publication Date
CN102597770A CN102597770A (zh) 2012-07-18
CN102597770B true CN102597770B (zh) 2016-08-10

Family

ID=42983318

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080051671.0A Expired - Fee Related CN102597770B (zh) 2009-09-15 2010-09-14 α-甲基葡萄糖苷(AMG)作为葡萄糖吸收和排泄的指示剂的用途

Country Status (7)

Country Link
US (1) US8147801B2 (OSRAM)
EP (1) EP2478357A1 (OSRAM)
JP (1) JP5722901B2 (OSRAM)
CN (1) CN102597770B (OSRAM)
AU (1) AU2010295722B2 (OSRAM)
IN (1) IN2012DN02711A (OSRAM)
WO (1) WO2011034846A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714905B1 (en) * 2017-11-21 2025-01-22 Solvex Limited Liability Company Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 3-o-methylglucose, and diagnostic method using said preparation
JP7570663B2 (ja) 2020-07-22 2024-10-22 国立大学法人群馬大学 糖尿病、肥満および／または脂肪肝に対する新規診断マーカーおよび新規治療用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1557178A1 (en) * 2002-10-29 2005-07-27 Takeda Pharmaceutical Company Limited Use of sglt homolog
CN1688596A (zh) * 2002-08-08 2005-10-26 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
CN1771334A (zh) * 2003-03-07 2006-05-10 施瑞修德制药公司 用于确定肿瘤对抗肿瘤药剂的治疗的敏感性的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540475B2 (ja) * 2002-08-08 2010-09-08 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP2005015460A (ja) * 2002-10-29 2005-01-20 Takeda Chem Ind Ltd Ｓｇｌｔホモログ用途
EA010655B1 (ru) * 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
EA015104B1 (ru) 2003-08-01 2011-06-30 Мицубиси Танабе Фарма Корпорейшн Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
JP2005139093A (ja) * 2003-11-05 2005-06-02 Nichirei Corp グルコース吸収阻害剤およびその製造方法
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
JP2009155212A (ja) * 2007-12-25 2009-07-16 Taisho Pharmaceutical Co Ltd Ｃ−フェニル１−チオグルシト−ル化合物を有効成分とする糖尿病治療剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688596A (zh) * 2002-08-08 2005-10-26 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
EP1557178A1 (en) * 2002-10-29 2005-07-27 Takeda Pharmaceutical Company Limited Use of sglt homolog
CN1771334A (zh) * 2003-03-07 2006-05-10 施瑞修德制药公司 用于确定肿瘤对抗肿瘤药剂的治疗的敏感性的方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Closed rat jejunal segment in situ: role of pre-epithelial diffusion resistance(unstirred layer) in the absorption process and model analysis.;D.Winne等;《Naunyn-Schmiedeberg"s Arch Pharmacol》;19871231;第335卷;第204-215页 *
Developmental study of α-methyl-D-glucoside and L-proline uptake in the small intestine of the white leghorn chicken.;M.Estrella Soriano, Joana M.Planas;《Poultry Science》;19981231;第77卷;第1347-1353页 *
Ethyl α-D-glucoside was absorbed in small intestine and excreted in urine as intact form.;Tomoyuki Mishima等;《Nutrition》;20051231;第21卷;第525-529页 *
Labeled glucose analogs in the genomic era.;S.John Gatley;《J Nucl Med》;20030731;第44卷(第7期);第1082页第1段 *
Separate transport systems for sugars and amino acids in developing rat kidney cortex.;Stanton Segal等;《Proc Nat Acad Sci USA》;19710228;第68卷(第2期);第372-376页 *
Synthesis and biologic evaluation of 11C-methyl-D-glucoside, a tracer of the sodium-dependent glucose transporters.;Guy M.Bormans等;《J Nucl Med》;20031231;第44卷;第1076页左栏倒数第2段，第1081页左侧栏第1段，表1 *
放射性核素标记脱氧葡萄糖类似物的研究进展;熊青峰，陈跃;《中华核医学杂志》;20070831;第27卷(第4期);第251页第四节 *

Also Published As

Publication number Publication date
JP5722901B2 (ja) 2015-05-27
US8147801B2 (en) 2012-04-03
EP2478357A1 (en) 2012-07-25
US20110065200A1 (en) 2011-03-17
AU2010295722B2 (en) 2015-04-16
AU2010295722A1 (en) 2012-04-12
IN2012DN02711A (OSRAM) 2015-09-11
WO2011034846A1 (en) 2011-03-24
JP2013504769A (ja) 2013-02-07
CN102597770A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
Ghezzi et al. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Ryder et al. Use of a novel impermeable biotinylated photolabeling reagent to assess insulin-and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients.
Wright et al. Novel and unexpected functions of SGLTs
Charles et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study
JP2019525198A (ja) 肝疾患関連バイオマーカーおよびその使用方法
EP2848254A1 (en) Pyrazole derivative and use thereof for medical purposes
US20150247839A1 (en) Cmpf as a biomarker for diabetes and associated methods
JP2019531261A (ja) 化合物、試薬およびその使用
US20140271474A1 (en) Inhibitor probes for imaging sodium-glucose cotransporters in health and disease
Zhang et al. Chloroquine pretreatment attenuates ischemia-reperfusion injury in the brain of ob/ob diabetic mice as well as wildtype mice
CN102597770B (zh) α-甲基葡萄糖苷(AMG)作为葡萄糖吸收和排泄的指示剂的用途
KR100251271B1 (ko) 위 상피 손상의 검출방법
Aires et al. Determination of the renal threshold for glucose excretion in familial renal glucosuria
WO2007128570A2 (de) In vitro verfahren zur erkennung und früherkennung und zur begleitenden kontrolle der therapie von arznei- und suchtmittelinduzierten leberschäden
Kovalenko et al. Current Problems of the Diagnostics and Treatment of Sepsis and Burn Injuries: The Modified Pathogenetic Concept
Zhang# et al. Differentiated serum levels of Krüppel-like factors 2 and 4, sP-selectin, and sE-selectin in patients with gestational diabetes mellitus
CA2959776A1 (en) Renal imaging agent
Hussein The journey of Sotagliflozin: from its status as a withdrawn candidate for the treatment of diabetes mellitus, to its repurposing as a groundbreaking drug for the management of heart failure.
JPWO2014088118A1 (ja) 心病変マーカー及びその利用
WO2000006207A1 (fr) Medicaments a vocation therapeutique permettant un diagnostic en rmn par liaison scalaire
TWI906076B (zh) 基於2-哌啶酮檢測大腸直腸癌的方法及其醫藥用途
Miloševski-Lomić et al. Integrated urinary biomarkers can predict early acute kidney injury in children undergoing chemotherapy
Alqudah Investigation Study of Cactus (Opuntia Ficus-Indica) Pads Juicing and Empagliflozin on HbA1c in Healthy and Induced Dm Type Ii Rats
Parry et al. Early Markers of Cardiac and Skeletal Muscle Metabolic Derangement in the Apc (min/+) Male Mouse
Zhao et al. Mechanisms of Bellidifolin in Treating Doxorubicin-Induced Cardiotoxicity: Network Pharmacology, Molecular Docking, and Experimental Verification

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160810